公司表示，基于积极的I期临床试验结果，三叶草生物计划将在2025年启动临床试验，用于评估SCB-1019（未使用佐剂的二价RSV-A/B候选疫苗）在RSV疫苗重复接种以及呼吸道联合疫苗的应用情况。Clover Bio-B (02197) rose by more than 14%. As of press release, it rose 14.75% to HK$0.35, with a turnover of HK$0.8356 million.
The Zhitong Finance App learned that Clover Bio-B (02197) rose by more than 14%. As of press release, it had risen 14.75% to HK$0.35, with a turnover of HK$0.8356 million.
According to the news, Clover Biotech announced this morning that it obtained more positive immunogenicity and safety data in elderly subjects after evaluating the unused adjuvant bivalent RSV preF-trimer subunit vaccine candidate SCB-1019 (development of Trimer-Tag - protein trimerization vaccine technology platform) and GSK's RSVAREXVY vaccine using the AS01E adjuvant in a phase I clinical trial.
The company said that based on positive phase I clinical trial results, Clover Bioplan will launch clinical trials in 2025 to evaluate the application of SCB-1019 (bivalent RSV-A/B vaccine candidate without adjuvants) in repeated doses of the RSV vaccine and respiratory combination vaccines.
